Bioheart Inc.  (BHRT) Trade Now »     Rate BHRT  -  Discuss BHRT  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BHRT: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bullish on BHRT ... BHRT

62%

Bioheart, Inc. Announces Private Funding Commitments of Up to $7 Million Wednesday February 4, 11:28 am ET SUNRISE, Fla., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc., (NasdaqCM:BHRT - News) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, announced today that it has entered into a non-binding letter of intent with Organic Business Alliances, LLC (``Organic'') pursuant to which it would invest approximately $1.5 million in Bioheart under its current offering under Regulation D and, subje... Continue reading »

Bioheart Inc. BHRT

N/A

Bioheart Reports Year End 2008 Results; Reviews 2008 and 1Q09 Progress and 2009 Business Objectives On Thursday May 7, 2009, 7:00 am EDT SUNRISE, Fla., May 7, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Other OTC:BHRT.PK - News) reports financial results for the year ended December 31, 2008, provides a review of its progress in 2008 and 1Q 2009 and outlines 2009 annual business objectives. Bioheart's Form 10-K was filed on April 15, 2009 and Bioheart's Form 10-K/A was filed on April 30, 2009. Highlights 1Q 2009 * Completed call center set up to support at-home heart failure mo... Continue reading »

Stem Cell Index Down 7% in Past Week BHRT

73%

Stem Cell Index Down 7% in Past Week <> By Mike Havrilla on 2/15/09 The table at my website link below includes 26 companies in the ETF Innovators Emerging Stem Cell Index, which lost 7% of its market value in the past week (at 1,148 today) and posted a 15.2% loss over the past year on an equal-weight basis. http://www.etfinnovators.com/2009/02/stem-cell-index-down-7-i... Results for benchmark indexes and ETFs include gains of 1.5% for the Cosmetic and Restorative Medicine Index and losses of 1.2% for SPDR S&P Biotech (XBI), 18.7% for Healthcare Sector... Continue reading »

Bullish on BHRT ... BHRT

62%

Bioheart, Inc. Announces Private Funding Commitments of Up to $7 Million Wednesday February 4, 11:28 am ET SUNRISE, Fla., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc., (NasdaqCM:BHRT - News) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, announced today that it has entered into a non-binding letter of intent with Organic Business Alliances, LLC (``Organic'') pursuant to which it would invest approximately $1.5 million in Bioheart under its current offering under Regulation D and, subje... Continue reading »

Stem Cell Index Down 1% in Past Week BHRT

73%

Stem Cell Index Down 1% in Past Week By Mike Havrilla on 2/9/09 ETF Innovators, LLP   <> The table at my website link below includes 29 companies in the ETF Innovators (ETFI) Emerging Stem Cell Index, which lost about 1% of market value in the past week and posted an 8.5% loss over the past year on an equal-weight basis. Results for benchmark indexes and ETFs include gains of 1.5% for SPDR S&P Biotech (XBI) and 1.2% for the ETFI Cosmetic and Reconstructive Medicine Index and losses of 17.4% for Healthcare Sector SPDR (XLV), 3.7% for iShares Nasdaq Biotech (IBB), a... Continue reading »

From the Blogosphere

Global Stem Cell and Regenerative Medicine Index

73%

The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close today. As previously, I will track the total market value for a more comprehensive gauge of investor sentiment toward the space. The index is down 16.2% over the past year on an equal-weight basis, compared to losses... Continue reading »

Stem Cell Index Down 7% in Past Week

73%

The accompanying table (click to enlarge) includes 26 companies in the ETF Innovators Emerging Stem Cell Index, which lost 7% of its market value in the past week (at 1,148 today) and posted a 15.2% loss over the past year on an equal-weight basis. Results for benchmark indexes and ETFs include gains of 1.5% for the Cosmetic and Restorative Medicine Index and losses of 1.2% for SPDR S&P Biotech (XBI), 18.7% for Healthcare Sector SPDR (XLV), 7.2% for iShares Nasdaq Biotech (IBB), and 17.7% for PowerShares Biotech & Genome (PBE). The next catalyst expected for stem cell and regenerative medicin... Continue reading »

Stem Cell Index Down 1% in Past Week

73%

<>The accompanying table (click to enlarge) includes 29 companies in the ETF Innovators (ETFI) Emerging Stem Cell Index, which lost about 1% of market value in the past week (at 1,242 today) and posted an 8.5% loss over the past year on an equal-weight basis. Results for benchmark indexes and ETFs include gains of 1.5% for SPDR S&P Biotech (XBI) and 1.2% for the ETFI Cosmetic and Reconstructive Medicine Index and losses of 17.4% for Healthcare Sector SPDR (XLV), 3.7% for iShares Nasdaq Biotech (IBB), and 14.5% for PowerShares Biotech & Genome (PBE). The next catalyst expected for stem cell and... Continue reading »

An Expanded Emerging Stem Cell Index

73%

The accompanying table (click to enlarge) includes 32 companies in the ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks with market caps below $250M. I will maintain the index with these 32 components and track the total market value and stock price changes as an indicator of investor and trader sentiment toward the stem cell and regenerative medicine space. Below is a list of all 32 companies in descending order by market cap with a total value of $1.27B and an average stock price change of -15% over the past year for the index, as compared to losses of 20% for the Healthcare S... Continue reading »

New Emerging Stem Cell Index

73%

Shares of Geron (GERN) and other well known stem cell and regenerative medicine stocks such as Osiris Therapeutics (OSIR) and StemCells (STEM) have been soaring since the FDA allowed human clinical testing for Geron's embryonic stem cell treatment candidate for spinal cord injuries. The accompanying table (click to enlarge) highlights 25 U.S.-listed stem cell and regenerative medicine companies with market caps of below $200M which are included in the ETF Innovators Emerging Stem Cell Index. The companies are also listed below in descending order by market cap. BioMimetic Therapeutics (BMTI) C... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.